Arcturus Therapeutics Holdings Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Meiji Seika Pharma purchased $50 million of Arcturus securities at $20.27/share (80% premium to prior pricing), representing 7.9% post-transaction ownership. Concurrently, Arcturus granted Meiji an exclusive license for ARCT-154 technology in an undisclosed therapeutic area and signed an MOU for pandemic preparedness collaboration in Japan. Proceeds will accelerate ARCT-2601 (OTC deficiency) development and validate LUNAR 2.0 platform.
Why this rating
Strategic $50M capital infusion is 15.5% of company market cap; validates platform, funds key pipeline milestone, signals third-party confidence despite undisclosed license scope.
Tradability signal
NO TRADE
No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.23 ▼ 0.11% | at our read · unknown $9.24 | +10 min · unknown $8.79 ▼ 4.85% | +30 min · unknown $8.86 ▼ 4.17% | +1 hr · unknown $8.68 ▼ 6.11% | +4 hrs · unknown $8.51 ▼ 7.89% |
The stock had already moved +0.11% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.